Collplant Holdings (CLGN) has released an update.
CollPlant Biotechnologies reported Q1 2024 financial results, noting a net loss increase and a cash balance of $23.2 million. The company highlighted its advancements in regenerative breast implants and ESG commitments, alongside a patent grant for its photocurable dermal filler product. Ongoing large-animal trials and development partnerships, such as with AbbVie, signal CollPlant’s continued innovation in regenerative and aesthetic medicine.
For further insights into CLGN stock, check out TipRanks’ Stock Analysis page.
